by Miguel-Angel Perales
Miguel-Angel Perales, MD, FASTCT, is the senior author of “ASTCT Consensus Grading for Immune Effector Cell-Associated Toxicities 2026 Update.” In this Q&A, he discusses the...
by Roisin E. O'Cearbhaill, MD
In this Meet the Author Q&A, Roisin E. O'Cearbhaill, MD, discusses the ASTCT-SITC white paper on advancing cell therapies for solid tumors, highlighting key biological, operational, and...
by Dr. Akshay Sharma, MBBS, MSc, Dr. María Cancio, MD
Akshay Sharma, MD, MBBS, MSc, and María Cancio, MD, are the authors of “Gene Therapy for Sickle Cell Disease: Practice Recommendations From the American Society for Transplantation and...
by Stephen Spellman
Stephen Spellman, a leader at CIBMTR and NMDP, shares insights into key trends shaping hematopoietic cell transplantation and cellular therapy. In this video, he highlights how immunobiology...
by Hemalatha Rangarajan, MD
Dr. Hemalatha Rangarajan of Nationwide Children’s Hospital (Columbus, Ohio) discusses new CIBMTR findings on pediatric and young adult AML, showing that extramedullary disease (EMD) at...
by Zahra Mahmoudjafari
Explore expert insights from ASTCT on building scalable, safe CGT (cell and gene therapy) programs, including key infrastructure, operational strategies, and sustainability considerations. This...